行业周报：中国香港房价及租金回暖，市场维持美国年内两次降息预期

Investment Rating - The investment rating for the social services industry is "Positive" (maintained) [1] Core Insights - The report highlights a robust recovery in the Hong Kong economy, with GDP growth of 3.5% in 2025 and a notable increase in retail sales, which rose by 5.5% year-on-year in January 2026 [25][27] - The residential property market in Hong Kong is showing signs of recovery, with the leading index rising by 8% year-on-year as of February 22, 2026, indicating a positive trend in housing prices [28][30] - The medical aesthetics sector, particularly the company "四环医药," is experiencing significant growth, with revenues exceeding 1.4 billion yuan and profits over 700 million yuan in 2025, reflecting a year-on-year growth rate of over 90% [43][44] Summary by Sections Government Work Report - The 2026 government work report emphasizes boosting consumption as a core strategy for expanding domestic demand, introducing measures to increase income for low-income groups and enhance consumer spending capacity [13][14] - New policies include a 100 billion yuan special fund to promote domestic demand and support for service consumption [13][16] Economic Recovery in Hong Kong - Hong Kong's economy is on a steady recovery path, with GDP growth of 3.5% in 2025 and a 3.8% increase in Q4, driven by both consumption and exports [26][27] - Retail sales are projected to reach approximately 410 billion HKD in 2026, marking an 8% year-on-year increase, with significant growth expected in jewelry, clothing, and cosmetics [27] Real Estate Market Trends - The residential property market is recovering, with the leading index reaching 149.41 points, an 8% increase year-on-year, and the private residential price index showing a 4.9% increase, marking eight consecutive months of growth [28][32] - The "cooling" measures in the property market have been fully implemented, reducing transaction costs and stimulating market liquidity [38][39] Medical Aesthetics Sector - The medical aesthetics division of "四环医药" is becoming a major revenue and profit driver, with a projected revenue of over 2.5 billion yuan in 2025, reflecting a growth rate exceeding 30% [43][44] - The company has a diverse product matrix, including successful products like "乐提葆" and "铂安润," which are contributing significantly to its revenue growth [48][49]